Paulson, A. Scott
Hess, Lisa M.
Liepa, Astra M.
Cui, Zhanglin Lin
Aguilar, Kathleen M.
Clark, Jamyia
Schelman, William
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 3 October 2017
Accepted: 14 January 2018
First Online: 3 February 2018
Compliance with ethical standards
:
: This study was funded Eli Lilly and Company.
: Dr. Paulson has advisory board roles at Taiho, Merrimack, Bristol Myers Squibb, and Advanced Accelerator Application, as well as owns stock in Juno and Immunomedics. Dr. Hess is employed by Eli Lilly and Company. Dr. Liepa is employed by and owns stock in Eli Lilly and Company. Dr. Cui is employed by and owns stock in Eli Lilly and Company. Ms. Aguilar is employed by McKesson Specialty Health and provided research consulting services to Eli Lilly and Company. Ms. Clark is employed by McKesson Specialty Health, owns stock in McKesson and provided research consulting services to Eli Lilly and Company. Dr. Schelman is employed by and owns stock in Eli Lilly and Company.
: Institutional Review Board and Compliance/Privacy approval was gained prior to initiation of the retrospective research. Since this project involved the analysis of existing data and records, study information was analyzed in such a manner that research participants could not be directly identified. Patient informed consent was not required due to the nature of the study design. Thus, exemption status and a waiver of informed consent were approved by The US Oncology, Inc. Institutional Review. Data was handled in compliance with HIPAA and Health Information Technology for Economic and Clinical Health (HITECH).